Condition: Lupus Erythematosus, Systemic · Lupus Erythematosus · Sponsor: Northwell Health
This two year study will evaluate the effects of giving belimumab (Benlysta) to patients with Early Lupus. Early lupus is a diagnosis of lupus within 2 years. Subjects will be randomized to receive belimumab or placebo during the first year. During the second year, subjects who were randomized to belimumab will be rerandomized to continue to receive belimumab or to receive placebo. The study will look at clinical effects as well as effects on the immune system.
This description comes directly from the study's public registry record.
Sanita Kandasami, BS · 516 562-2401 · skandasami@northwell.edu
Cynthia Aranow, MD · 516 562-3845 · caranow@northwell.edu
Always discuss trial participation with your own doctor first.
| Feinstein Institute | Manhasset, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03543839